Groundbreaking research presented at the San Antonio Breast Cancer Symposium suggests thousands of women with early-stage ...

Omission of surgical axillary staging is noninferior to sentinel-lymph-node biopsy for patients with clinically node-negative ...

This week, the Henry B. Gonzalez Convention Center is where leading doctors from all over have gathered to share research and ...

A "watch-and-wait" strategy might be the best option for some women with early-stage, low-risk breast cancer.

It's a decision no woman wants to have to make, but new research shows that young breast cancer patients with high-risk genes ...

A new study, published in the New England Journal of Medicine, examines whether removing lymph nodes is always necessary in ...

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk ...

Therapeutics highlights the infiltration of cancer fighting immune cells into tumors, using leading CD8 ImmunoPET imaging ...

Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), in partnership with the American Association for Cancer Research (AACR), is hosting the 47th ...

Tissue Penetration: Consistent with the recently updated trial protocol, tissue Css levels were evaluated in addition to plasma Css levels. The 80 mg/day dose, in both treatment arms, achieved tissue ...

Tempus, a leader in artificial intelligence and precision medicine, today announced four abstracts were accepted for ...

Additional new data will show how Myriad’s second-generation tumor-informed molecular residual disease (MRD) assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, ...